Article

Longitudinal SPECT study in Alzheimer's disease: Relation to apolipoprotein E polymorphism

Department of Neurology, Kuopio University Hospital and University of Kuopio, Finland.
Journal of Neurology Neurosurgery & Psychiatry (Impact Factor: 5.58). 07/1998; 64(6):742-6. DOI: 10.1136/jnnp.64.6.742
Source: PubMed

ABSTRACT In mild Alzheimer's disease, SPECT imaging of regional cerebral blood flow has highlighted deficits in the posterior association cortex, and later in the disease process, the deficit spreads to involve the frontal cortex. The sigma4 allele of apolipoprotein E is a risk factor for Alzheimer's disease. The effect of apolipoprotein E polymorphism on cerebral perfusion was studied. The hypothesis was that those patients with Alzheimer's disease who carry the sigma4 allele would have more severe cerebral hypoperfusion.
Thirty one patients with Alzheimer's disease and eight age and sex matched control subjects were examined in a three year longitudinal study. Patients with Alzheimer's disease were divided into subgroups according to their number of sigma4 alleles. Regional cerebral blood flow ratios referred to the cerebellum were examined by 99mTc-HMPAO SPECT. Apolipoprotein E genotypes were determined by digestion of polymerase chain reaction products with the restriction enzyme Hha1.
All patients with Alzheimer's disease had bilateral temporoparietal hypoperfusion compared with control subjects. The two sigma4 allele subgroups had the lowest ratios at the baseline assessment in the parietal and occipital cortices, and at the follow up in the temporal, parietal, and occipital cortices. They had the highest reduction in percentage terms in the temporal and occipital cortices compared with the other subgroups. However, the global clinical severity did not differ at the baseline or follow up examinations between the subgroups.
Apolipoprotein E polymorphism is involved in the pathogenesis and heterogeneity of Alzheimer's disease as the most severe cerebral hypoperfusion was found in the sigma4 allele subgroups. This might have implications for therapeutic approaches in Alzheimer's disease.

Download full-text

Full-text

Available from: Hilkka Soininen, Aug 25, 2015
0 Followers
 · 
80 Views
  • Source
    • "In these cases, the most comprehensive study, in terms of having the largest sample sizes and widest breadth of cognitive ability measures, was chosen to represent the research groups. The resultant articles included were Bondi et al. (1999), Caselli et al. (2002), Helkala et al. (1996), Lehtovirta et al. (1995), and Smith et al. (1998). The only exception was the inclusion of two articles by Wilson and colleagues (Wilson, Bienias, et al., 2002; Wilson, Schneider, et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The epsilon4 allele of the apolipoprotein E (APOE) gene is a known risk factor for Alzheimer's disease and may also affect cognitive performance in normal aging. Evidence of the presence and magnitude of epsilon4-related cognitive deficits was examined with a meta-analysis of the available literature. Thirty-eight studies were included, and cognitive performance was collapsed into 8 domains. Results indicated significant APOE-epsilon4 group differences for global cognitive functioning, episodic memory, and executive functioning, in favor of non-epsilon4 carriers. In addition, older age and APOE-epsilon4 heterozygosity was associated with smaller epsilon4-related impairments. The meta-analysis results suggest that APOE-epsilon4 genotype does affect cognitive performance in healthy aging, although the influence is relatively small and specific to certain domains of cognitive performance.
    Psychology and Aging 01/2005; 19(4):592-600. DOI:10.1037/0882-7974.19.4.592 · 2.73 Impact Factor
  • Source
    • "At least one study has addressed how ApoE genotype can influence the beta-amyloid burden both in MTL (the entorhinal cortex) and the frontal cortex [21]. It was found, Table 3 Cerebral blood flow and metabolism studies and apolipoprotein E Authors Study design Conclusions Small et al. 1995, PET-study 38 volunteers at risk for dementia: 12 ⑀4 Ϫ non AD, 19 ⑀4ϩ non AD and 7 AD patients Right-left parietal asymmetry: ⑀4ϩ Ͼ ⑀4Ϫ subjects Parietal CMR: ⑀4ϩ Ͻ ⑀4Ϫ subjects Reiman et al.1996, PET-study 33 volunteers at risk for dementia: 22 ⑀4Ϫ/ Ϫ and 11 ⑀4ϩ/ϩ subjects Posterior cingulate, parietal, temporal and prefrontal CMR: ⑀4 ϩ/ϩ Ͻ ⑀4ϩϪ/Ϫ subjects Lehtovirta et al. 1996, SPECT 58 AD patients: 21 ⑀4Ϫ/Ϫ, 24 ⑀4ϩ/Ϫ, 13 ⑀4 ϩ/ϩ patients, and 34 age-matched controls Left occipital perfusion: ⑀4ϩ/ϩ Ͻ ⑀4Ϫ/Ϫ, ⑀4 ϩ/Ϫ patients Corder et al. 1997, PET-study 46 subjects: 31 AD, 3 non-AD, and 12 mild memory complaints, 25 ⑀4Ϫ, 21 ⑀4ϩ subjects No differences between ⑀4ϩ and ⑀4Ϫ subjects Higuchi et al. 1997, PET-study 20 AD patients: 6 ⑀4Ϫ/Ϫ, 10 ⑀4ϩ/Ϫ, 4 ⑀4ϩ/ϩ patients Frontal CMR: ⑀4ϩ/ϩ Ͼ ⑀4ϩ/Ϫ Ͼ ⑀4Ϫ/Ϫ Hirono et al. 1998, PET-study 83 AD patients: 35 ⑀4Ϫ, 48 ⑀4ϩ patients No association between CMR and ApoE Lehtovirta et al. 1998, SPECT 31 AD patients: 10 ⑀4Ϫ/Ϫ, 13 ⑀4ϩ/Ϫ, 8 ⑀4ϩ/ϩ patients and 8 age-matched controls Temporal, occipital, and parietal perfusion: ⑀4ϩ/ϩ Ͻ ⑀4ϩ/Ϫ, ⑀4Ϫ/Ϫ patients Mielke et al. 1998, PET-study 49 AD patients: 20 ⑀4Ϫ, 29 ⑀4ϩ patients ⑀4 allele is an independent predictor of tempoparietal and frontal hypometabolism Tanaka et al. 1998, SPECT 34 AD patients: 22 ⑀4Ϫ, 12 ⑀4ϩ patients and 22 age-matched controls Temporal lobe perfusion: ⑀4ϩ Ͻ ⑀4Ϫ patients Van Dyck et al. 1998, SPECT 52 AD patients: 22 ⑀4Ϫ, 30 ⑀4ϩ patients and 14 healthy volunteers Parietal perfusion asymmetry: ⑀4Ϫ Ͼ ⑀4ϩ patients CMR ϭ cerebral metabolic rate. that the levels of beta amyloid were increased in both regions in parallel with the increasing number of ⑀4 alleles. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The epsilon 4 allele of apolipoprotein E is a risk factor for Alzheimer's disease, but also a modulator of its clinical picture. In this paper, recent research in neuroimaging of aging and Alzheimer's disease in relation to apolipoprotein E is reviewed, emphasizing the advances but also the controversies. Further, the possible clinicopathological implications of these findings are discussed.
    Neurobiology of Aging 03/2000; 21(2):293-300. DOI:10.1016/S0197-4580(00)00120-2 · 4.85 Impact Factor
  • Source
Show more